Vertex Pharmaceuticals Inc. announced that it has received FDA approval for the use of Trikaftaยฎ for children with cystic fibrosis ages 2 to 5 years who have at least one copy of the F508del mutation or certain mutations that are responsive to lab data.
Reminder: After every pediatric clinic visit in-person or virtually, you will be invited to share your feedback in the Experience of Care Survey. Please complete so we can make your clinic visit even better!
Visit our website at https://t.co/5QgSqsCbmJ. Slides from Ed Day have been uploaded. When on the site, follow CF Education day link on the left hand side.
CF Education Day, this Saturday, March 18th! We've extended the deadline, if you haven't already registered for CF Education day, please scan the QR code below